KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacific Biosciences Of California (PACB) Non-cash Items (2013 - 2022)

Pacific Biosciences Of California's quarterly Non-cash Items came in at $125.1 million in Q4 2022, up 1.79% year-on-year from $122.9 million in Q4 2021, and up 1.79% quarter-over-quarter from $122.9 million in Q4 2021.

Pacific Biosciences Of California has reported Non-cash Items for 10 years, with the latest figure at $125.1 million in Q4 2022.

  • For the quarter ending Q4 2022, Non-cash Items rose 1.79% year-over-year to $125.1 million; the trailing twelve-month figure through Dec 2022 stood at $125.1 million (up 1.79% YoY), and the FY2022 full-year result was $125.1 million, up 1.79% from the prior year.
  • Non-cash Items for Q4 2022 stood at $125.1 million, up from $122.9 million in the prior quarter.
  • The five-year high for Non-cash Items was $298.8 million in Q4 2020, with the low at $20.0 million in Q4 2019.
  • Average Non-cash Items over 5 years is $125.0 million, with a median of $122.9 million recorded in 2021.
  • Year-over-year, Non-cash Items soared 3311.76% in 2018 and slumped 65.52% in 2019.
  • Tracing PACB's Non-cash Items over 5 years: stood at $58.0 million in 2018, then tumbled by 65.52% to $20.0 million in 2019, then soared by 1394.0% to $298.8 million in 2020, then plunged by 58.87% to $122.9 million in 2021, then grew by 1.79% to $125.1 million in 2022.
  • The last three Non-cash Items figures came in at $125.1 million (Q4 2022), $122.9 million (Q4 2021), and $298.8 million (Q4 2020), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Abbott Laboratories 152.82 Bn 146.17 Bn 6.27 Bn
2 Stryker 115.07 Bn 112.19 Bn 3.81 Bn
3 Medtronic 95.25 Bn 87.08 Bn 5.76 Bn
4 Boston Scientific 71.38 Bn 70.17 Bn 3.61 Bn
5 Edwards Lifesciences 51.08 Bn 47.41 Bn 1.29 Bn
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn
7 Dexcom 28.84 Bn 27.72 Bn 750.30 Mn
8 GE HealthCare Technologies 28.56 Bn 26.49 Bn 1.98 Bn
9 Steris 20.71 Bn 20.30 Bn 697.10 Mn
10 Pacific Biosciences Of California 481.66 Mn 205.70 Mn 12.84 Mn

Historic Data

Download Data 🔒
DateValue
Dec 31, 2022 125.10 Mn
Dec 31, 2022 125.10 Mn
Dec 31, 2021 122.90 Mn
Dec 31, 2021 122.90 Mn
Dec 31, 2020 298.80 Mn
Dec 31, 2020 298.80 Mn
Dec 31, 2019 20.00 Mn
Dec 31, 2019 20.00 Mn
Dec 31, 2018 58.00 Mn
Dec 31, 2018 58.00 Mn
Dec 31, 2017 1.70 Mn
Dec 31, 2017 1.70 Mn
Dec 31, 2016 7.30 Mn
Dec 31, 2016 7.30 Mn
Dec 31, 2015 145.40 Mn
Dec 31, 2015 145.40 Mn
Dec 31, 2014 53.30 Mn
Dec 31, 2014 53.30 Mn
Dec 31, 2013 15.40 Mn
Dec 31, 2013 15.40 Mn